Smith+Nephew launches new total ankle and total shoulder replacement technologies; showcases recently acquired Extremity Orthopaedics portfolio at AAOS

LONDON, Aug. 31, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces it will feature its recently expanded Extremities portfolio at the American Academy of Orthopaedic Surgeons 2021 Annual Meeting being held in San Diego, CA. The exciting new portfolio is the result of acquiring the Extremity Orthopaedics business of Integra LifeSciences earlier in 2021, and includes solutions for upper and lower extremity arthritis, and fracture management of the shoulder, elbow, wrist, hand, foot and ankle.

Smith+Nephew is also announcing the full market release of two key products in the total ankle and total shoulder replacement segments - the CADENCE Total Ankle Flat Cut Talar Dome System and ATLASplan™ Shoulder 3D Planning and patient-specific instrument (PSI) System.

The CADENCE Total Ankle Flat Cut Talar Dome (System) expands Smith+Nephew's continuum of care for patients with end stage ankle arthritis. The new system allows surgeons to treat a wide range of patients with varying anatomy and deformity for primary and revision procedures, while simultaneously addressing the customer segment that is looking for the efficiency of a surgical approach with one simple cut on the talus.

David Pedowitz, MD, MS, FAAOS of Rothman Orthopaedic Institute implanted the first CADENCE Flat Cut Talar Dome ankle prosthesis and commented, "The flat cut talar dome is a great addition to the CADENCE portfolio that broadens the deformities I can address without taking away from the streamlined instrumentation and advanced anatomic design that CADENCE is known for."

The CADENCE System has garnered positive feedback among surgeons for advancements in implant and instrument design, along with a streamlined surgical technique. It incorporates features designed to help reduce potential clinical complications, accommodate various patient anatomies, and address common challenges with ankle arthroplasty.

ATLASplan software was developed in conjunction with Materialise– a leader in 3D planning and printing for medical applications. It provides a web-based, user-friendly interface for shoulder arthroplasty preoperative planning as well as a patient-specific surgical guide that utilizes the base of the coracoid for stability allowing for reproducible guide pin placement. ATLASplan 3D planning along with patient specific instrumentation is designed to facilitate greater accuracy in the OR¹ compared to 2D imaging without templating. An optional PSI system can be ordered to help a surgeon translate the preoperative plan to the OR. 

"The ATLASplan software allows me to fully review a patient's anatomy in both its current and pre-morbid state, and develop an operative game plan prior to stepping foot in the OR," said Matthew Ramsey, MD, of the Rothman Institute and a design surgeon of the Titan™ Shoulder System.

To learn more about our new Extremities portfolio, please stop by the Smith+Nephew booth (#1735) during AAOS 2021.

About Smith+Nephew
Smith+Nephew is a portfolio medical technology business that exists to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 18,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $4.6 billion in 2020. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

™ Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.

View original content to download multimedia:https://www.prnewswire.com/news-releases/smithnephew-launches-new-total-ankle-and-total-shoulder-replacement-technologies-showcases-recently-acquired-extremity-orthopaedics-portfolio-at-aaos-301365736.html

SOURCE Smith & Nephew plc